Thiopurines with Low-dose Allopurinol (ThiLDA)-a Prospective Clinical One-way Crossover Trial

Overview

Journal Eur J Clin Pharmacol

Specialty Pharmacology

Date 2019 Oct 7

PMID 31587102

Citations 1

Authors

S Faraz Chavoushi

Bindia Jharap

Philip Friedrich

Kees Smid

Godefridus J Peters

Mirte Malingre

Affiliations

Soon will be listed here.

Abstract

Purpose: Many patients with Crohn's disease (CD) and ulcerative colitis (UC) who have a high 6-methylmercaptopurine/6-thioguanine (6-MMP/6-TGN) ratio receive allopurinol 100 mg in addition to thiopurines to optimize metabolite concentrations. However, some patients do not tolerate allopurinol at this dosage. The aim of this study was to determine the intra-patient effect of reducing the allopurinol dosage from 100 to 50 mg, in terms of metabolite concentrations, enzyme activities, efficacy, and tolerability.

Methods: A prospective non-inferiority one-way crossover study was performed. CD and UC patients with stable disease using a thiopurine and allopurinol 100 mg were switched to 50 mg for 1 month. Primary outcomes were thiopurine metabolite concentrations. Secondary outcomes were enzyme activities of xanthine oxidase, thiopurine methyltransferase and hypoxanthine-guanine phosphoribosyltransferase, disease activity, and tolerability.

Results: Twenty-two patients were included. Treatment with allopurinol 50 mg compared with 100 mg resulted in a significant decrease in mean 6-TGN levels (761 to 625 pmol/8 × 10 RBC; p = 0.005) and a significant increase in mean 6-MMP levels (451 to 665 pmol/8 × 10 RBC; p = 0.01). However, the mean metabolite concentrations were still therapeutic. Enzyme activities, disease activity scores, and patient experiences did not alter significantly. Generally, UC patients were more positive about their improved treatment than CD patients.

Conclusion: Combination therapy with 50 mg allopurinol led to a decrease of 6-TGN levels compared with 100 mg allopurinol. Disease activity, side effects, and patient experience, however, were similar between allopurinol 100 and 50 mg. UC patients seem to benefit and prefer lower doses whereas the contrary is seen in CD patients.

Trial Registration: EudraCT trial registry - number 2016-001638-84.

Citing Articles

Steroidal Antimetabolites Protect Mice against .

Chaudhuri M, Singha U, Vanderloop B, Tripathi A, Nes W Molecules. 2022; 27(13).

PMID: 35807334 PMC: 9268410. DOI: 10.3390/molecules27134088.

References

Sparrow M, Hande S, Friedman S, Lim W, Reddy S, Cao D . Allopurinol safely and effectively optimizes tioguanine metabolites in inflammatory bowel disease patients not responding to azathioprine and mercaptopurine. Aliment Pharmacol Ther. 2005; 22(5):441-6. DOI: 10.1111/j.1365-2036.2005.02583.x. View

Smith M, Blaker P, Marinaki A, Anderson S, Irving P, Sanderson J . Optimising outcome on thiopurines in inflammatory bowel disease by co-prescription of allopurinol. J Crohns Colitis. 2012; 6(9):905-12. DOI: 10.1016/j.crohns.2012.02.007. View

Gomollon F, Dignass A, Annese V, Tilg H, Van Assche G, Lindsay J . 3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn's Disease 2016: Part 1: Diagnosis and Medical Management. J Crohns Colitis. 2016; 11(1):3-25. DOI: 10.1093/ecco-jcc/jjw168. View

Harbord M, Eliakim R, Bettenworth D, Karmiris K, Katsanos K, Kopylov U . Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management. J Crohns Colitis. 2017; 11(7):769-784. DOI: 10.1093/ecco-jcc/jjx009. View

Dubinsky M . Optimizing immunomodulator therapy for inflammatory bowel disease. Curr Gastroenterol Rep. 2003; 5(6):506-11. DOI: 10.1007/s11894-003-0041-7. View

Hoentjen F, Seinen M, Hanauer S, de Boer N, Rubin D, Bouma G . Safety and effectiveness of long-term allopurinol-thiopurine maintenance treatment in inflammatory bowel disease. Inflamm Bowel Dis. 2012; 19(2):363-9. DOI: 10.1002/ibd.23021. View

Curkovic I, Rentsch K, Frei P, Fried M, Rogler G, Kullak-Ublick G . Low allopurinol doses are sufficient to optimize azathioprine therapy in inflammatory bowel disease patients with inadequate thiopurine metabolite concentrations. Eur J Clin Pharmacol. 2013; 69(8):1521-31. DOI: 10.1007/s00228-013-1500-1. View

Gardiner S, Gearry R, Burt M, Chalmers-Watson T, Chapman B, Ross A . Allopurinol might improve response to azathioprine and 6-mercaptopurine by correcting an unfavorable metabolite ratio. J Gastroenterol Hepatol. 2010; 26(1):49-54. DOI: 10.1111/j.1440-1746.2010.06489.x. View

Jharap B, Seinen M, De Boer N, Ginkel J, Linskens R, Kneppelhout J . Thiopurine therapy in inflammatory bowel disease patients: analyses of two 8-year intercept cohorts. Inflamm Bowel Dis. 2010; 16(9):1541-9. DOI: 10.1002/ibd.21221. View

10.

Prefontaine E, MacDonald J, Sutherland L . Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease. Cochrane Database Syst Rev. 2010; (6):CD000545. DOI: 10.1002/14651858.CD000545.pub3. View

11.

Sparrow M, Hande S, Friedman S, Cao D, Hanauer S . Effect of allopurinol on clinical outcomes in inflammatory bowel disease nonresponders to azathioprine or 6-mercaptopurine. Clin Gastroenterol Hepatol. 2007; 5(2):209-14. DOI: 10.1016/j.cgh.2006.11.020. View

12.

Dervieux T, Meyer G, Barham R, Matsutani M, Barry M, Boulieu R . Liquid chromatography-tandem mass spectrometry analysis of erythrocyte thiopurine nucleotides and effect of thiopurine methyltransferase gene variants on these metabolites in patients receiving azathioprine/6-mercaptopurine therapy. Clin Chem. 2005; 51(11):2074-84. DOI: 10.1373/clinchem.2005.050831. View

13.

Candy S, Wright J, Gerber M, Adams G, Gerig M, Goodman R . A controlled double blind study of azathioprine in the management of Crohn's disease. Gut. 1995; 37(5):674-8. PMC: 1382873. DOI: 10.1136/gut.37.5.674. View

14.

Timmer A, McDonald J, Tsoulis D, MacDonald J . Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev. 2012; (9):CD000478. DOI: 10.1002/14651858.CD000478.pub3. View

15.

Govani S, Higgins P . Combination of thiopurines and allopurinol: adverse events and clinical benefit in IBD. J Crohns Colitis. 2010; 4(4):444-9. PMC: 3157326. DOI: 10.1016/j.crohns.2010.02.009. View

16.

Seinen M, van Asseldonk D, De Boer N, Losekoot N, Smid K, Mulder C . The effect of allopurinol and low-dose thiopurine combination therapy on the activity of three pivotal thiopurine metabolizing enzymes: results from a prospective pharmacological study. J Crohns Colitis. 2013; 7(10):812-9. DOI: 10.1016/j.crohns.2012.12.006. View